Novartis, GSK, Lilly offer mixed bag of Q3 earnings

Third-quarter earnings season is in full swing, with several Big Pharma--and not-so-big-yet-still-key pharma--reporting numbers over the past 24 hours. Here's the latest.

  • Novartis posted increases in both profits and sales--10 percent and 13 percent, respectively--but the company warned of ongoing pricing pressures from global healthcare reforms. The acquisition of 77 percent of Alcon was a major push toward revenues of $12.58 billion; strong sales of the cancer drug Gleevec, diabetes remedy Galvus, and its new generic competitor for Sanofi-Aventis' Lovenox also helped. Novartis release | Report | Report

  • Cost-cutting boosted Eli Lilly's profits by 38 percent to $1.3 billion, or $1.18 per share, beating Wall Street estimates. But its $5.65 billion in sales missed expectations, and analysts said they're worried by impending generic competition for Lilly's top-selling drugs. "Overall, a reasonable quarter for the company, yet for many investors, it is the longer-term financial outlook that matters more and here, Lilly still looks challenged," Sanford Bernstein's Tim Anderson says in a note to investors (as quoted by Reuters). Eli Lilly release | ReportReport

  • GlaxoSmithKline's earnings slipped 1 percent in the third quarter, but still beat analyst estimates; sales, however, weren't up to par. Profits were hit by the cost of writing off stocks of the recently restricted diabetes drug Avandia and by increased generic competition for its herpes drug Valtrex. "Once these year-over-year pressures subside, we expect GSK to become a growth stock," UBS' Gbola Amusa tells BloombergGSK's report | Report | Report

  • Baxter reported a 12 percent increase in profit, after last year's one-time charges; the company posted $595 million in profits on sales of $3.22 billion. The biggest growth segment: its medication-delivery operations, which grew 5.3 percent. Baxter release | Report | Report

  • Genzyme earnings ratcheted upward significantly as supplies of its drugs for rare diseases get back to normal after a plant shutdown last year. Profits grew to $69 million, or 26 cents per share, on sales of $1 billion. Sales of its Cerezyme drug for Gaucher disease beat analyst estimates, but Fabrazyme revenues fell short. Genzyme release | Report | Report

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.